论文部分内容阅读
目的:观察复肝注射液治疗中晚期肝癌的临床疗效。方法:将50例患者随机分组治疗,对照组20例采用介入治疗,观察组30例采用复肝注射液配合介入治疗。观察治疗前后的主观症状、体重、病灶、生存期、生活质量卡氏评分、生化指标、免疫指标、AFP值变化及毒副反应的出现情况。结果:综合治疗可明显改善患者症状,提高生活质量,稳定并增加体重,延长1、2年生存率,观察组AFP、ALT、GGT、ALP、CD8等指标均显著降低,CD4/CD8明显升高,以上各指标改善情况均优于对照组,且不良反应较少。结论:复肝注射液是治疗中晚期肝癌的有效药物,且能减轻介入化疗的毒副作用。
Objective: To observe the clinical efficacy of Fugan injection in the treatment of advanced liver cancer. Methods: 50 patients were randomized to treatment, 20 patients in the control group were treated with interventional therapy, 30 patients in the observation group were treated with Fugan Injection and interventional therapy. Observed the subjective symptoms before and after treatment, body weight, lesions, survival time, quality of life, Kjeldahl, biochemical indicators, immune indicators, changes in AFP values and the occurrence of toxic side effects. Results: Comprehensive treatment can significantly improve the symptoms of patients, improve the quality of life, stabilize and increase weight, and prolong the 1-year and 2-year survival rate. The observation group AFP, ALT, GGT, ALP, CD8 and other indicators were significantly reduced, and CD4/CD8 was significantly increased. The improvement of the above indicators was better than that of the control group, and there were fewer adverse reactions. Conclusion: Fugan injection is an effective drug for the treatment of advanced liver cancer, and can reduce the toxic side effects of interventional chemotherapy.